Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 4/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471837 | 0.90 | ELOVL6 (0.39) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL22968848 | 0.90 | ELOVL6 (0.39) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL2467594 | 0.89 | CYP46A1 (0.38) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL2467309 | 0.87 | CYP46A1 (0.37) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL29410287 | 0.87 | CYP46A1 (0.37) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL2470993 | 0.87 | CYP46A1 (0.37) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL2471187 | 0.81 | MDM2 (0.44) | MEN1KMT2AAKR1B1MDM2IDO1 | |
| SCHEMBL2468966 | 0.81 | CYP2C19 (0.36) | MAPTKMT2AAKR1B1 | |
| SCHEMBL2468741 | 0.81 | CYP46A1 (0.37) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL2472750 | 0.78 | CYP46A1 (0.43) | CYP46A1NR1I2NR3C1PGRADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | claimed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | claimed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | claimed |
| EP-1858520-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| EP-1858520-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | CYP46A1 3124/4885NR1I2 1438/4885NR3C1 4247/4885 |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | CYP46A1 3124/4885NR1I2 1438/4885NR3C1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.